三阴性乳腺癌（TNBC）：非遗传肿瘤异质性和免疫微环境：新兴治疗选择。
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.
机构信息
Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Department of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
出版信息
Pharmacol Ther. 2022 Sep;237:108253. doi: 10.1016/j.pharmthera.2022.108253. Epub 2022 Jul 21.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor heterogeneity and lack of biomarkers are thought to be some of the most difficult challenges driving therapeutic resistance and relapse. This review will summarize current therapy for TNBC, studies in treatment resistance and relapse, including data from recent single cell sequencing. We will discuss changes in both the transcriptome and epigenome of TNBC, and we will review mechanisms regulating the immune microenvironment. Lastly, we will provide new perspective in patient stratification, and treatment options targeting transcriptome dysregulation and the immune microenvironment of TNBC patients.
摘要
三阴性乳腺癌（TNBC）是一种侵袭性亚型，其特征为广泛的肿瘤内异质性，并经常对治疗产生耐药性。肿瘤异质性和缺乏生物标志物被认为是导致治疗耐药和复发的最困难挑战之一。本综述将总结 TNBC 的当前治疗方法、治疗耐药和复发的研究，包括最近单细胞测序的数据。我们将讨论 TNBC 的转录组和表观基因组的变化，并综述调节免疫微环境的机制。最后，我们将提供新的视角，即针对 TNBC 患者转录组失调和免疫微环境的患者分层和治疗选择。
相似文献
1
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.三阴性乳腺癌（TNBC）：非遗传肿瘤异质性和免疫微环境：新兴治疗选择。
Pharmacol Ther. 2022 Sep;237:108253. doi: 10.1016/j.pharmthera.2022.108253. Epub 2022 Jul 21.
2
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.三阴性乳腺癌的免疫治疗：现存挑战与振奋前景。
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
3
Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.三阴性乳腺癌微环境中的新型 miRNA 靶点和治疗方法：一种具有挑战性疾病的新兴希望。
Int J Mol Sci. 2020 Nov 24;21(23):8905. doi: 10.3390/ijms21238905.
4
Triple-negative breast cancer: advancements in characterization and treatment approach.三阴性乳腺癌：特征及治疗方法的进展
Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239.
5
Programmed cell death-related prognostic genes mediate dysregulation of the immune microenvironment in triple-negative breast cancer.程序性细胞死亡相关预后基因介导三阴性乳腺癌免疫微环境的失调。
Front Immunol. 2025 Mar 12;16:1563630. doi: 10.3389/fimmu.2025.1563630. eCollection 2025.
6
Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.三阴性乳腺癌中的表观遗传调控：对肿瘤微环境的治疗意义
Pharmacol Res. 2024 Jun;204:107205. doi: 10.1016/j.phrs.2024.107205. Epub 2024 May 6.
7
Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.鉴定一个基因表达特征，以预测三阴性乳腺癌的早期复发风险和免疫细胞浸润程度。
Cancer Genomics Proteomics. 2024 May-Jun;21(3):316-326. doi: 10.21873/cgp.20450.
8
Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.长非编码 RNA：在人类非三阴性和三阴性乳腺癌的靶向诊断、预后和改进治疗策略中的意义。
Clin Epigenetics. 2018 Jun 27;10:88. doi: 10.1186/s13148-018-0514-z. eCollection 2018.
9
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.三阴性乳腺癌免疫检查点阻断反应的生物标志物。
Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4.
10
Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.回顾性转录组谱分析鉴定出可能受益于免疫检查点和 PARP 抑制剂的泰国三阴性乳腺癌患者。
PeerJ. 2023 Jun 12;11:e15350. doi: 10.7717/peerj.15350. eCollection 2023.
引用本文的文献
1
The Prediction Model for Triple-Negative Breast Cancer Prognosis and Immunotherapy Efficacy Based on Single-Cell Sequencing of CD8+ T cells.基于CD8+T细胞单细胞测序的三阴性乳腺癌预后及免疫治疗疗效预测模型
J Cancer. 2025 Jul 24;16(11):3343-3354. doi: 10.7150/jca.115507. eCollection 2025.
2
Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple-Negative Breast Cancer.靶向小细胞外囊泡中的网蛋白4（RTN4）可对抗三阴性乳腺癌转移并增强免疫治疗效果。
J Extracell Vesicles. 2025 Aug;14(8):e70154. doi: 10.1002/jev2.70154.
3
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer.三阴性乳腺癌中与种族相关的宿主和微生物转录组特征
NPJ Breast Cancer. 2025 Aug 8;11(1):87. doi: 10.1038/s41523-025-00806-y.
4
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer.长链非编码RNA NORAD作为肿瘤发生的促进因子，并通过miR-144-3p-mTOR-铁蛋白自噬轴在癌症中抑制铁死亡。
Eur J Med Res. 2025 Aug 4;30(1):704. doi: 10.1186/s40001-025-02998-2.
5
Quercetin: A Natural Ally in Combating Breast Cancer.槲皮素：对抗乳腺癌的天然盟友。
Int J Nanomedicine. 2025 Jul 19;20:9155-9177. doi: 10.2147/IJN.S518174. eCollection 2025.
6
Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy.术前炎症状态作为接受新辅助治疗的三阴性乳腺癌患者的一个积极预后因素。
Medicine (Baltimore). 2025 Jul 11;104(28):e42208. doi: 10.1097/MD.0000000000042208.
7
Artificial intelligence-driven discovery of YH395A: A novel TGFβR1 inhibitor with potent anti-tumor activity against triple-negative breast cancer.人工智能驱动发现YH395A：一种对三阴性乳腺癌具有强效抗肿瘤活性的新型转化生长因子β受体1（TGFβR1）抑制剂。
Cell Commun Signal. 2025 Jul 8;23(1):326. doi: 10.1186/s12964-025-02337-2.
8
Immune-based molecular subtyping of triple-negative breast cancer via SNF-CC and functional validation of key immune-associated genes.通过SNF-CC对三阴性乳腺癌进行基于免疫的分子亚型分类及关键免疫相关基因的功能验证。
Funct Integr Genomics. 2025 Jul 8;25(1):148. doi: 10.1007/s10142-025-01654-6.
9
Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance.单细胞和空间组学在解读癌症药物反应和耐药性细胞特征中的应用。
J Hematol Oncol. 2025 Jul 2;18(1):70. doi: 10.1186/s13045-025-01722-1.
10
A 'two-missile' nanoplatform for targeting triple-negative breast cancer: prodrug activation and immune enhancement.一种用于靶向三阴性乳腺癌的“双导弹”纳米平台：前药激活与免疫增强
Mater Today Bio. 2025 May 20;32:101891. doi: 10.1016/j.mtbio.2025.101891. eCollection 2025 Jun.
本文引用的文献
1
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer.化疗联合巨噬细胞抑制可诱导三阴性乳腺癌中 T 细胞和 B 细胞浸润和持久消退。
Cancer Res. 2022 Jun 15;82(12):2281-2297. doi: 10.1158/0008-5472.CAN-21-3714.
2
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
3
MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.MUC1-C 决定癌症干细胞中增强子特征的 JUN 和 BAF 介导的染色质重塑。
Mol Cancer Res. 2022 Apr 1;20(4):556-567. doi: 10.1158/1541-7786.MCR-21-0672.
4
Hallmarks of Cancer: New Dimensions.癌症的特征：新视角。
Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
5
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.卡培他滨辅助治疗早期乳腺癌：一项随机试验的 15 年总生存结果。
J Clin Oncol. 2022 Apr 1;40(10):1051-1058. doi: 10.1200/JCO.21.02054. Epub 2022 Jan 12.
6
Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.鉴定具有预测三阴性乳腺癌新辅助化疗反应潜力的 DNA 甲基化生物标志物。
Clin Epigenetics. 2021 Dec 18;13(1):226. doi: 10.1186/s13148-021-01210-6.
7
New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.戈沙妥珠单抗-hziy治疗转移性三阴性乳腺癌的新数据。
Clin Adv Hematol Oncol. 2021 Nov;19(11):723-725.
8
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.三阴性乳腺癌的治疗现状——选择增多，需求变化。
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. doi: 10.1038/s41571-021-00565-2. Epub 2021 Nov 9.
9
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.多组学分析鉴定三阴性乳腺癌亚型的治疗脆弱性。
Nat Commun. 2021 Nov 1;12(1):6276. doi: 10.1038/s41467-021-26502-6.
10
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.复制压力反应缺陷与非高突变癌症中免疫检查点阻断的反应相关。
Sci Transl Med. 2021 Oct 27;13(617):eabe6201. doi: 10.1126/scitranslmed.abe6201.
Zotero 插件